Aeglea BioTherapeutics to Present New 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 SSIEM Symposium
29. August 2019 08:30 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions...
Aeglea BioTherapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights
06. August 2019 08:00 ET
|
Aeglea BioTherapeutics, Inc.
FDA Breakthrough Therapy Designation Received for Pegzilarginase in Treatment of Arginase 1 Deficiency Dosed First Patient in Global Pivotal Phase 3 PEACE Trial New Data from Arginase 1 Deficiency...
Aeglea BioTherapeutics Receives FDA Breakthrough Therapy Designation for Pegzilarginase for Treatment of Arginase 1 Deficiency
24. Juli 2019 16:05 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, July 24, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions...
Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 Deficiency
03. Juni 2019 08:30 ET
|
Aeglea BioTherapeutics, Inc.
Topline Data from PEACE Anticipated in First Quarter of 2021 New Data from ARG1-D Phase 1/2 Extension Study Expected in September 2019 AUSTIN, Texas, June 03, 2019 (GLOBE NEWSWIRE) -- Aeglea...
Aeglea BioTherapeutics to Participate in Upcoming Investor and Industry Conferences
30. Mai 2019 08:30 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, May 30, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions...
Aeglea BioTherapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights
07. Mai 2019 07:45 ET
|
Aeglea BioTherapeutics, Inc.
Statistically Significant Reductions in Plasma Arginine with Accompanying Clinical Improvements with Pegzilarginase in Phase 1/2 Reaffirm Pivotal Trial Design Gross Proceeds of $69 Million from...
Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
07. April 2019 19:15 ET
|
Aeglea BioTherapeutics, Inc.
Consistent, Marked, and Sustained Lowering of Elevated Plasma Arginine with Pegzilarginase Clinically Impactful Responses Captured by Mobility and Adaptive Behavior Assessments Management to Host...
Aeglea BioTherapeutics to Present Updated Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency in an Oral Presentation at the 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
01. April 2019 08:00 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, April 01, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...
Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences
28. März 2019 08:30 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, March 28, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights
07. März 2019 16:05 ET
|
Aeglea BioTherapeutics, Inc.
On Track to Dose First Patient in Pivotal Phase 3 Trial of Pegzilarginase for ARG1-D in Q2 of 2019 Initiated IND-Enabling Studies for New Pipeline Programs Progress with Pegzilarginase Cancer...